News

Promising Results for Vutrisiran in Cardiac Amyloidosis

Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the company. The HELIOS-B study met the primary endpoint, showing a statistically significant reduction, compared with placebo, in the composite of all-cause mortality and recurrent cardiovascular events

Racial, Gender Inequities in CGRP, Gepant Prescriptions

Racial, Gender Inequities in CGRP, Gepant Prescriptions

SAN DIEGO, California — A review of prescription patterns reveals calcitonin gene-related peptide (CGRP) and gepant medications for migraine reveals significant gender and racial disparities that may affect access to care and health equity. “The study serves as an early steppingstone in identifying opportunities for further research and intervention to expand access to migraine therapeutics,”